Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Oruka Therapeutics, Inc.’s reported figures.
The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 4:01 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055769
FAQ
- What is Oruka Therapeutics, Inc.'s EBIT?
- Oruka Therapeutics, Inc. (ORKA) reported EBIT of -$36.43M in Q1 2026.
- How has Oruka Therapeutics, Inc.'s EBIT changed year-over-year?
- Oruka Therapeutics, Inc.'s EBIT decreased by 45.2% year-over-year, from -$25.09M to -$36.43M.
- What is the long-term trend for Oruka Therapeutics, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Oruka Therapeutics, Inc.'s EBIT has grown at a 58.5% compound annual growth rate (CAGR), from -$19.34M to -$122.05M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Oruka Therapeutics, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude